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Promoting patient safety in primary care
Honesty and openness may not be best
policy
Editor—We were both surprised by Wilson
et al who, in their editorial, ask everybody to
send in reports of their errors.1 Our
concerns remain regardless of whether or
not such accounts are published anony›
mously. After all, the police have used
anonymous medical research data in their
investigations. A conviction of culpable and
reckless behaviour was secured against a
man after he had sexual intercourse with his
girlfriend without telling her he was infected
with HIV. The scientific evidence that
secured the conviction came from confiden›
tial research data that were obtained with a
police warrant.2
Furthermore, Wilson et all say that for
doctors to report their errors, patient
consent will be needed. This means that the
patient will know that an account of his or
her care is to be published and may read it.
He or she may ask his lawyers to read it. The
lawyers may then be able to substantiate this
published account as a confession of guilt or
negligence.
Wherever and whoever we are, we must
be careful as doctors what we say. For exam›
ple, although we understand that no charges
were brought, an incident last year high›
lights this point. Police are to hold a murder
inquiry into the case of Peter Brand, a Mem›
ber of Parliament for the Liberal Democrat
Party for the Isle of Wight and a general
practitioner, who mentioned during a
parliamentary debate that he had withdrawn
treatment from a two year old boy with leu›
kaemia at the parents’ request, to save him
any more distress.3 This case had occurred in
1973, when he was a house officer.
However regrettable, we do live in a
culture of blame. To admit professional mis›
takes of a minor nature may be straightfor›
wardly forgivable. The admission, however,
of a serious offence or negligence by doctors
may result in litigation against them. Before
discussing such matters in public, doctors
should seriously consider whether honesty
and openness are the best policy.
Graham Ness clinical lecturer in forensic psychiatry
g.j.ness@sheffield.ac.uk
Christopher Cordess chair of academic section of
forensic psychiatry
School of Health and Related Research, Sheffield
University, Sheffield S1 4DA
1 Wilson T, Pringle M, Sheikh A. Promoting patient safety in
primary care. BMJ 2001;323:582›3. (15 September.)
2 Dyer C. Use of confidential HIV data helps convict former
prisoner. BMJ 2001;322:633.
3 Dyer C. Police question medical MP over “euthanasia.”BMJ
2000;320:464.
Practices should set up their own critical
incident reporting
Editor—The editorial by Wilson et al on
promoting patient safety in primary care
serves as a prompt to develop appropriately
designed incident reporting systems.1 The
publication of Organisation with a Memory2
and Doing Less Harm3 and the recent launch
of the National Patient Safety Agency have
firmly set the agenda for risk management
in both secondary and primary care.
Learning to identify and manage our
risks in primary care could be seen as an
opportunity to enhance and focus continu›
ing professional development, team work›
ing, and cultural change. Cultural change
should be characterised, in part, by risk
awareness, openness, and the opportunity
for anonymous and blame free risk and inci›
dent reporting within our organisations, by
any team member.
Sheikh and Hurwitz have highlighted
the importance of developing primary
medical error databases.4 This should come
from within the profession if we are to incul›
cate a sense of realism and ownership in
practices in readiness for mandatory inci›
dent reporting.
In our practice colleagues and I have
classified 25 types of adverse event. These
include administrative and organisational,
communication, and health and safety events
and a range of clinical events (including
diagnostic, therapeutic and prescribing, pro›
cedural, and case management “errors").
This is underpinned by a reporting system
that takes account of the reporter’s narrative
and can be anonymous if required. Events
are coded and stored on a secure computer,
with the classified events recorded on dated
spreadsheets with hyperlinks to the report›
er’s narrative, the analysis of root causes, and
necessary actions as text files.
This will be enhanced by a more sophis›
ticated database in due course, but this rela›
tively simple approach has enabled us to get
started by using our existing office software.
This was relatively easy; the real work will lie
in developing the culture and making the
changes to reduce our risks and improve
patient care. But if we can do it anyone can.
Steve Ruffles general practitioner
Portland Medical Practice, Aldridge, West Midlands
WS9 8NS
RufflesS@gp.walsall›ha.wmids.nhs.uk
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Should NHS patients be
allowed to pay extra for their
care?
Patient payments bring new resources
into system
Editor—Richards et al in their article raise
the issue of patients contributing to pay›
ments for cancer drugs in Britain’s NHS.1 It
is pleasing to see that times are changing for
ethics committees even if the pervasive tone
of self righteousness is a bit grating. If British
politicians cannot manage to improve the
NHS, why should a patient not pay for drug
treatment perceived as beneficial? Would the
group consider it unethical for a patient to
pay for vitamin pills, special diets, alternative
medicine, or a second opinion?
Over the next three years there is going
to be a major shift in cancer care. New
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molecularly targeted medicines that block
specific signalling pathways and angiogen›
esis will become available. These will take the
form of simple tablets, to be taken once a
day. They will prolong survival by a few
months in many cancers, but as the
predictive power of genomics and proteom›
ics bites, cancer will become a chronic,
controllable disease. The cost will exceed the
budget of Britain’s national cancer plan,
which is just a catching up exercise on 30
years of underinvestment by successive gov›
ernments. In a global society no group of
armchair ethicists sitting in Nottingham can
stop people ordering these new drugs
through the internet and paying with their
credit card. Debating the issue is futile.
What we can do is to ensure that the
core cancer services offered to everyone by
the NHS improve. The cancer plan provides
an excellent structure but is underfunded.
Creating the new bureaucracy has provided
excellent spin for politicians who think they
have “done cancer.” The reality is grim—
ageing radiotherapy machines, clear exam›
ples of continuing postcode prescribing,
overworked staff, and lack of consultation
time. Allowing patients to pay for treatments
outside the core is one way of bringing addi›
tional resources into the system. Another is
to privatise their delivery.
Karol Sikora visiting professor of cancer medicine
Hammersmith Hospital, London W12 0HS
karolsikora@hotmail.com
1 Richards C, Dingwall R, Watson A. Should NHS patients
be allowed to contribute extra money to their care? BMJ
2001;323:563›5. (9 September.)
Debate is essential, not futile
Editor—Richards et al raise many ethical
and legal issues, discussing whether or not
NHS patients should be allowed to contrib›
ute extra money to their care.1 In his rapid
response and the letter above Sikora argues
that debating the issue is futile.2 I believe that
extensive debate by all stakeholders in the
NHS is essential. This new class of “active”
patient, wealthy enough to purchase expen›
sive pharmacogenomic drugs such as
Herceptin (trastuzumab), could add a new,
unbalancing component to shared decision
making, by rendering clinicians scarcely
more than technicians. The effect on the
research process would do a disservice to
fellow patients with breast cancer and be
disruptive to equitable and evidence based
provision of health care in general in a
health provision system that is based on
egalitarian principles such as we have in the
United Kingdom.
An editorial in the Lancet described the
political activism of the national breast can›
cer coalition in the United States that,
according to its president, brought Hercep›
tin to women two years earlier than this
would have happened without its advocacy.3
This attitude may bring benefits to its mem›
bers but does not redress the balance of
power in the research community.4 The con›
duct and quality of research globally would,
however, be further diminished by ad hoc
personal purchasing. Cultural differences
and different systems of healthcare
provision—for example between the United
States and the United Kingdom—would
probably result in even more divisive
availability of treatments.
Furthermore, patients who have pur›
chased such an expensive drug are not likely
to agree to its administration only within the
restraints of a trial protocol, where informed
consent to test for eligibility and participa›
tion in the trial will be required. Trials are
needed to establish the drug’s efficacy in
patients with early breast cancer. Will
patients who purchase Herceptin also be
allowed to sidestep testing for HER2 expres›
sion, which is necessary to determine
eligibility for its use (where only 25›30% of
primary breast cancers express the HER2
protein), thereby avoiding the discrimina›
tory potential of the genetic test (which is
only 80% accurate) for this type of breast
cancer, for which the prognosis is worse?5 It
will make the treatment of breast cancer
even more discriminatory if there is a
further subdivision of patients who can
either pay for it or pay for it and receive it
outside of the context of a clinical trial, thus
delaying production of data even longer.
Problems of consent and information provi›
sion to participants of prospective trials will
be particularly difficult with this new class of
drugs, without the added problem of ad hoc
purchasing.
Hazel Thornton independent advocate for quality in
research and healthcare
Saionara, 31 Regent Street, Rowhedge, Colchester
CO5 7EA
hazelcagct@aol.com
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Pragmatism should rule, not policy
committees
Editor—The approach at our cancer centre
has been different to that reported in the
paper by Richards et al.1 For non›funded
cancer drugs, patients have been advised
that they may continue under the care of
their NHS consultant, who will supervise the
administration of the cytotoxic agent as
usual. The only difference from normal
practice is that the hospital pharmacy sends
an invoice for the drug cost to the patient.
Although this is not perfect, it is satisfactory
for the patient who requires a particular
treatment that is otherwise unavailable on
the NHS and who is willing and able to pay.
Richard Osborne consultant in medical oncology
Dorset Cancer Centre, Poole Hospital, Poole,
Dorset BH15 2JB
rjosborne@csi.com
1 Richards C, Dingwall R, Watson A. Should NHS patients
be allowed to contribute extra money to their care? BMJ
2001;323:563›5. (9 September.)
Charges for NHS dental care have led to
privatisation
Editor—Richards et al asked whether
patients in the NHS should be allowed to
contribute extra money to their care. In
NHS dental primary care charges to
patients have been high for over 10 years.1
NHS patients pay up to £360 towards just
one course of treatment, and these charges
now account for 80% of the full cost of most
dental treatments performed in the NHS.
So have these patient charges improved
NHS dental care? In theory, they should
have, through additional funding, but after
only a few years the government deducted
any payments from patients from govern›
ment payments to dentists, leaving us as
unpaid tax collectors with no more funding
and a lot more extra paperwork.
With many patients paying such high
NHS charges, it was, however, a small step to
ask patients to pay the full costs, or to join a
low cost plan at about £12 per month to
receive the high quality private dentistry that
the government is unprepared to allow or
fund properly in the NHS.
So additional patient charges are a good
thing—they help the public to start “valuing”
medical services while initially providing
some additional funds. If the government
stays true to form and starts to count
charges to patients as government funds,
deducting these from grants, etc, then at
least offering private quality care will be one
step nearer for the public.
Modern patient care must come before
thinking like a third world government, even
if that means funding care outside the NHS.
This is now well established in dental care in
the United Kingdom, and medicine would
do well to learn from NHS dentistry’s prob›
lems and solutions.
Tony Kilcoyne dental practitioner
Dental Practice, Haworth, West Yorkshire
BD22 8NL
care@smilespecialist.co.uk
1 Richards C, Dingwall R, Watson A. Should NHS patients
be allowed to contribute extra money to their care? BMJ
2001;323:563›5. (9 September.)
Screening for Down’s
syndrome
Antenatal screening has human costs
Editor—In their study Gilbert et al made no
provision for the cost of counselling.1 I still
hear from women who go for antenatal care
and are screened without consent or
counselling.1 2 Some of these women regret
entering a conveyor belt process that ends
up with an invasive procedure that causes a
high rate of fetal loss. Gilbert et al, by
highlighting the economic implications of
screening, remind us that mothers and their
unborn babies continue to be used in what is
primarily a cost saving procedure.
Doubt has already been cast upon the
public health benefits of screening and the
ethical component of such programmes.3
No pregnancy is replaceable. The cost of
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screening in human terms has not been
evaluated. By excluding the costs of counsel›
ling and disregarding mothers’ rights and
the worth and value to society of children
with Down’s syndrome, the study by Gilbert
et al has severe limitations that should
prevent us from embracing such screening
strategies.
Josephine Venn›Treloar general practice assistant
The Surgery, Welling, Kent DA16 2JZ
atreloar@globalnet.co.uk
1 Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Scul›
pher M, et al. Screening for Down’s syndrome: effects,
safety, and cost effectiveness of first and second trimester
strategies. BMJ 2001;323:423›5. (25 August.)
2 J Venn›Treloar J. Nuchal translucency›screening without
consent. BMJ 1998;316:1026.
3 C Ford. The value of screening for Down’s Syndrome in a
socio›economically deprived area with a high ethnic
population. Br J Obstet Gynaecol 1998;105:855›9.
Costings are crucial to model
Editor—Gilbert et al in their paper provide
an analysis of cost and effectiveness of
screening for Down’s syndrome using math›
ematical modelling.1 Costing of procedures
undertaken in the NHS is difficult, and
Gilbert et al conclude that four screening
strategies are cost effective and efficient.
Nuchal translucency screening is appar›
ently the cheapest procedure, at £4.40 per
test, but there is no indication how this figure
was derived. In a cost analysis undertaken
for ultrasound scanning for the Royal
College of Obstetrics and Gynaecology in
1995, the cheapest scan cost about £35.2
This figure was probably unreliable, but the
discrepancy is large, and it is important to
resolve it since the costs Gilbert et al quote
for nuchal translucency screening are
crucial to their model. If the costing is inac›
curate then the conclusions of the study are
likely to be incorrect.
The literature generally agrees that
nuchal translucency screening together with
serum testing seems an efficient screening
method, which is confirmed by this model.
But the practical problems that surround
implementation of such a programme
nationally are formidable. Only about 7% of
units are offering nuchal translucency
screening. There are well recognised short›
ages of radiography staff and possibly
inadequate facilities in some circumstances.
Early screening demands effective counsel›
ling before a woman gets to the hospital, so
she has time to consider her options.
One of the benefits of an early diagnosis
is a surgical termination, but in this model
only about one third of women had their
diagnosis in time. Early diagnosis also
increases the demand for chorionic villus
sampling, which is generally available only
in fetal medicine centres, carries a higher
miscarriage rate than amniocentesis and
incurs higher laboratory costs. Currently
about 60% of women in the United
Kingdom are offered at least a double test.
Gilbert et al indicate the weakness of
that strategy, but it is a starting point, and the
addition of other analytes would not
necessarily be difficult. Screening is likely to
be more feasible to support during the
second trimester than during the first,
mainly because of the difficulties of imple›
menting nuchal translucency measure›
ments. This model suggests that a quadruple
test may prove effective, and, although there
would be an increased cost, the test entails
automated, laboratory techniques and not
those dependent on a skill—such as nuchal
translucency screening. The challenge is to
find a technique that is not only cost effective
and safe but that is also feasible to
implement nationally.
Martin Whittle chairman, antenatal subgroup of
national screening committee
Department of Fetal Medicine, Birmingham
Women’s Hospital, Birmingham B15 2TG
m.j.whittle@bham.ac.uk
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strategies. BMJ 2001;323:423›5. (25 August.)
2 Royal College of Obstetrics and Gynaecology. Ultrasound
screening for fetal abnormalities. Report of the RCOG Working
Party. London: RCOG, 1995.
Conclusions do not reflect reality
Editor—Gilbert et al have tried to identify
the best approach for screening for Down’s
syndrome.1 They have, however, fallen into
the trap of uncritically evaluating the pub›
lished literature. There is no statistical proof
that the detection rate is significantly better
for any of triple screening versus double
screening, quadruple screening versus dou›
ble or triple screening, or screening in the first
trimester versus the second trimester, or that
the integrated test is an improvement.2
All studies of Down’s syndrome screen›
ing have had small numbers of examples of
pregnancies positive for Down’s. Conse›
quently, although false positive rates can be
accurately assessed, the detection rate
cannot. The confidence intervals about the
detection rate are so wide that no one has
yet proved that the superiority of one
method over another is not entirely due to
chance.2 It has also been known for a long
time that where small numbers have been
used to derive a population model that is
used to estimate false positive and detection
rates, large errors can result from an error in
the estimate of the population variance for a
single analyte giving rise to a hopelessly
optimistic estimate of the effectiveness of a
procedure.3
Studies of the efficacy of nuchal translu›
cency screening have all been interven›
tional, and the quoted detection rate (of the
order of 80%) therefore needs to be deflated
to account for natural fetal losses. The effect
of natural fetal loss is to reduce the detection
rate for screening during the first trimester
to less than 60%, making it comparable to
screening during the second trimester.4 In
addition, for nuchal translucency measure›
ment, there is a far greater incidence of fail›
ure to be able to make a measurement than
there is failure of biochemical testing to be
able to produce a result, which further
depresses the detection rate.
Finally, there are serious statistical doubts
about the integrated test and worries about
the ethics of withholding early positive results
until a second test has been performed.5 The
unit costs estimated for the different tests are
also interesting. How can it be that an
ultrasound test requiring 15›20 minutes of
hands on technical work is cheaper than a
biochemical test, when one person can
analyse hundreds of samples per day?
Since the detection rates for nuchal
translucency screening are grossly overesti›
mated and the integrated test is expensive
and unproved, the conclusion that these two
modalities of screening represent the
boundary of cost effectiveness cannot be left
unchallenged.
Tim Reynolds consultant chemical pathologist
Queen’s Hospital, Burton›on›Trent, Staffordshire
DE13 0RB
tim.reynolds@queens.burtonh›tr.wmids.nhs.uk
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2 Reynolds TM. Downs syndrome screening: A controversial
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2000;53:893›8.
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statistical overview. In: Screening for Down’s syndrome.
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Cambridge: Cambridge University Press, 1994:47›71.
4 Reynolds T. Antenatal screening for Down’s syndrome.
Lancet 1998:352;1145.
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ing for Down’s syndrome. New Engl J Med 1999:341;
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Modelling does not predict reality
accurately
Editor—Gilbert et al conclude that, of the
antenatal screening tests for Down’s syn›
drome, the integrated test is the most
effective and safest strategy and that all other
strategies result in more liveborn babies or
miscarriages of unaffected pregnancies.1
Their conclusions are derived from math›
ematical modelling rather than trial data.
This is particularly true when evaluating the
integrated test, which has never been tested
in a controlled trial nor even in a large
uncontrolled demonstration project.
It is difficult to think of any other area of
medicine where health policy is so driven by
modelling without the support of properly
gathered clinical evidence. There are no
controlled studies showing that serum or
nuchal translucency screening is more effec›
tive than maternal age or reduces the rates
at which invasive procedures are performed.
By contrast, there is clear evidence that
modelling does not accurately predict the
effectiveness of screening programmes in
practice. We reported a 68% antenatal
detection rate over six years, screening by
maternal age where routine anomaly scan›
ning was also offered.2 Ford et al found that
serum screening detected only 31% of cases
of Down’s syndrome antenatally.3 The mod›
elling relied on by Gilbert predicts that in
the first study the detection rate should have
been 32% and in the second 60%.
Modelling does not predict reality accu›
rately for two reasons.
Firstly, women do not behave as
predicted. In Ford’s study only 71% accepted
screening, so only 13 of 19 cases occurred in
those screened.3 Only 11 of these 13 were
screen positive, of which only six had
invasive testing. Only four of the six chose
Letters
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termination. In other studies many older
mothers decline screening in favour of a
definitive diagnostic test, increasing the
amniocentesis rate above that predicted.
Secondly, modelling also fails because of
inaccurate assumptions about the age struc›
ture of the antenatal population. The
models assume that 5% of pregnant women
are aged over 35 whereas nationally the pro›
portion is 16.5% (launch of National
Sentinel Caesarean Section Audit). In
Southampton this resulted in over 65% of
cases of Down’s arising in older women.2
Finally, Gilbert et al do not consider
some of the negative impact of screening.
Women increasingly complain that mid›
wives and doctors are not interested in their
pregnancies until they have ruled out
Down’s syndrome. Age based screening
need be discussed with only a small segment
of the population, who are often aware when
planning their pregnancy of the higher risk
of Down’s. If we are to retain scientific cred›
ibility the choice of the best screening policy
should be made on the basis of evidence
from controlled clinical trials and not
models that are demonstrably inaccurate.
David Howe consultant in fetomaternal medicine
Wessex Fetal Medicine Unit, Princess Anne
Hospital, Southampton SO16 5YA
1 Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Scul›
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safety, and cost effectiveness of first and second trimester
strategies. BMJ 2001;323:423›5. (25 August.)
2 Howe DT, Gornall R, Wellesley D, Boyle T, Barber J. Six
year survey of screening for Down’s syndrome by maternal
age and mid›trimester ultrasound scans. BMJ 2000;320:
606›10.
3 Ford C, Moore AJ, Jordan PA, Bartlett WA, Wyldes MP,
Jones AF, et al. The value of screening for Down’s
syndrome in a socioeconomically deprived area with a
high ethnic population. Br J Obstetr Gynaecol 1998;105:
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Authors’ reply
Editor—The questions about costs raised
by Venn›Treloar, Whittle, and Reynolds
were addressed in the full text version of the
report on bmj.com, with further details in
the technical report (www.ich.ucl.ac.uk/srtu/
frampubs.htm).1 We included the costs of
counselling before amniocentesis, chorionic
villus sampling, or termination, but we
assumed that screening options were dis›
cussed with all women at booking. As all
women were assumed to have had a dating
ultrasound scan, the cost of the nuchal fold
translucency test relates to the additional
time to take measurements, explain the
results, and train ultrasonographers.
Reynolds seems to have missed the
section in the methods that explains that the
nuchal fold measurement was adjusted for
verification bias. Howe makes the case for a
modelling exercise. Differences between our
detection rates and those from studies based
on routine care will be strongly affected by
uptake rates, referral practices, and verifica›
tion bias. Modelling takes account of these
factors to allow comparison of test perform›
ance and would still be required even if trials
were feasible.
Finally, Reynolds raises an important
point about the poor precision of the detec›
tion rate. One approach is to look for
consistency of the characteristics of test per›
formance. Meta›analyses of the results for
biochemical markers produce compara›
tively precise results, which are consistent
with the characteristics used in the analysis.
But to take account of the correlation
between markers we used test characteristics
from a single large, archived dataset. Other
archived datasets have given similar results.2
We believe that this approach gives the best
estimates of test performance but accept
that random error is not represented.
R E Gilbert senior lecturer in clinical epidemiology
C Augood research fellow in systematic reviews
R Gupta research assistant in statistics
S Logan senior lecturer in epidemiology
Systematic Reviews Training Unit, Department of
Paediatric Epidemiology and Biostatistics,
A E Ades reader in biostatistics
Department of Paediatric Epidemiology and
Biostatistics, Institute of Child Health, London
WC1N 1EH
M Sculpher senior research fellow
Centre for Health Economics, University of York,
Heslington, York YO1 5DD
J H P van der Meulen senior lecturer in clinical
epidemiology
Health Services Research Unit, Department of
Public Health and Policy, London School of
Hygiene and Tropical Medicine, London
WC1E 7HT
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strategies. BMJ 2001;323:423›5. (25 August.)
2 Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal
screening for Down’s syndrome. J Med Screen 1997;4:181›
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Ratio of femoral length to tibial length
needs to be evaluated extensively
Editor—Gilbert et al and Howe et al in their
articles rely heavily on maternal age to
screen for Down’s syndrome.1 2 But maternal
age is not so useful in India and other coun›
tries where early marriage is the norm and
the social pressures for early motherhood
are enormous. In our series, which included
3000 deliveries and seven babies with
Down’s syndrome, we saw that all babies
with the syndrome were born to mothers
younger 35 years.
We reported in the American Journal of
Perinatology our finding that the ratio of
femoral length to tibial length remains
remarkably constant around 1.15 (range
1.13›1.19) in fetuses after 13 weeks’ gestation.3
Fetuses with Down’s syndrome had this ratio
greater than 1.2 (standard deviation 4.5)
compared with norms. The youngest fetus
with Down’s syndrome in our sample was 22
weeks old at the time of measuring. We hope
that this ratio will be evaluated more
extensively and earlier in pregnancy, to see if
these findings are valid in the early second
trimester and across ethnic groups.
Pooja Sachdev registrar in paediatrics
Shubhra Bahl senior house officer in paediatrics
Jacob M Puliyel consultant paediatrician
puliyel@vsnl.com
Department of Pediatrics, St Stephen’s Hospital,
Tis Hazari, Delhi 110054, India
1 Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Scul›
pher M, et al. Screening for Down’s syndrome: effects,
safety, and cost effectiveness of first and second trimester
strategies. BMJ 2001;323:423›5. (25 August.)
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Nuchal translucency screening may help
detect congenital heart disease
Editor—Screening for Down’s syndrome
during fetal life has received much attention,
with over 350 articles in the medical literature
over the past five years alone. The data on
cost effectiveness provided by Gilbert et al are
welcome, given the variable screening
strategies offered by different NHS providers.1
Increased nuchal translucency may be a
marker of many fetal diseases, and a
discussion of its cost effectiveness should not
be restricted to Down’s syndrome alone.
Congenital heart disease is the most
common type of fetal malformation (at least
8/1000 during fetal life), but only 25% of
clinically significant malformations are actu›
ally detected prenatally in the United
Kingdom,2 which is worse than any other
type of fetal anomaly. Increased nuchal
translucency is associated with congenital
heart disease, independent of karyotypic
abnormalities, with a sensitivity of 15›56%.3–5
Although far from perfect as a screening
tool for congenital heart disease, nuchal
scanning makes some contribution to
prenatal detection of congenital heart
disease and chromosomal abnormalities.
This is highly relevant when the relative
merits and cost effectiveness of prenatal
screening strategies are evaluated.
John M Simpson consultant in fetal and paediatric
cardiology
Department of Congenital Heart Disease,
Guy’s Hospital, London SE1 9RT
john.simpson@gstt.sthames.nhs.uk
1 Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Scul›
pher M, et al. Screening for Down’s syndrome: effects,
safety, and cost effectiveness of first and second trimester
strategies. BMJ 2001;323:423›5. (25 August.)
2 Bull C. Current and potential impact of fetal diagnosis on
prevalence and spectrum of serious congenital heart
disease at term in the UK. British Paediatric Cardiac
Association. Lancet 1999;354:1242›7.
3 Mavrides E, Cobian›Sanchez F, Tekay A, Moscoso G,
Campbell S, Thilaganathan B, et al. Limitations of using
first›trimester nuchal translucency measurement in rou›
tine screening for major congenital heart defects
Ultrasound Obstet Gynecol 2001;17:106›10.
4 Michailidis GD, Economides DL. Nuchal translucency
measurement and pregnancy outcome in karyotypically
normal fetuses. Ultrasound Obstet Gynecol 2001;17:102›5.
5 Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH.
Using fetal nuchal translucency to screen for major
congenital defects at 10›14 weeks of gestation: population
based cohort study. BMJ 1999;318:81›5.
Problems with temporary
cardiac pacing
Ultrasonography can aid central venous
cannulation
Editor—Murphy in his editorial highlights
problems with temporary cardiac pacing
where the service is provided by doctors in
training with inadequate supervision.1 An
essential component of temporary pacing is
obtaining central venous access. The failure
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rate for this intervention remains notable.
Murphy suggests involving anaesthetists or
intensivists to help resolve this problem.
There are other ways to address this
important issue rather than increasing the
workload of another department. The first
would be to increase the involvement of
consultant physicians from the current level
of only 14%. Failure rates for central venous
cannulation are related to the experience of
the operator, with failure rates almost
double in inexperienced hands.2
The second is to move from a landmark
guided technique for central venous cannu›
lation to an ultrasound guided technique. A
meta›analysis comparing ultrasound guid›
ance with a landmark technique for central
venous cannulation suggested that ultra›
sound guidance significantly reduced the
rates of failures and complications and the
need for multiple attempts at placement.3
The benefits may be more obvious in
patients with difficult central venous access.4
Paul Jefferson consultant in anaesthesia and intensive
care medicine
p.jefferson@dgri.scot.nhs.uk
Vincent Perkins consultant in anaesthesia and
intensive care medicine
Dumfries and Galloway Royal Infirmary, Dumfries
DG1 4AP
1 Murphy JJ. Problems with temporary cardiac pacing. BMJ
2001;323:527. (9 September.)
2 Sznajder JI, Zveibil FR, Bitterman H, Weiner P, Bursztein S.
Central vein catheterization. Failure and complication
rates by three percutaneous approaches. Arch Intern Med
1986;146:259›61.
3 Randolph AG, Cook DJ, Gonzales CA, Pribble CG.
Ultrasound guidance for placement of central venous
catheters: A meta›analysis of the literature. Crit Care Med
1996;24:2053›8.
4 Hatfield A, Bodenham A. Portable ultrasound for difficult
central venous access. BJA 1999;82:822›6.
Better training in general medicine is
required
Editor—Temporary transvenous cardiac
pacing is a life saving procedure and an
important skill for emergency physicians to
have.1 It is often a poorly taught procedure
with potentially life threatening complica›
tions. It should not be embarked on without
due care, attention, and training. When pos›
sible, waiting and observing more stable
patients overnight until the permanent
pacemaker list is much more desirable. But
potentially deskilling the frontline may have
equally disastrous consequences, as would
transferring potentially unstable patients to
other centres.
If trainees in general medicine are not to
expected to perform temporary pacing, then
should the same be said for chest drains, cen›
tral lines, and lumbar punctures? When
specialty medicine does cover 24 hours
patients will expect specialists performing
their particular skill, but further deskilling
general medical trainees in the current
climate may do more harm than good. What
we need is better training in general medicine
or an overhaul of acute medicine.
Tristan Richardson specialist registrar
Royal Bournemouth Hospital, Bourenmouth
BH7 7DW
tilrichardson@hotmail.com
1 Murphy JJ Problems with temporary cardiac pacing. BMJ
2001;323:527. (9 September.)
Training is essential
Editor—I was surprised to read in the
editorial by Murphy that one of his
proposed solutions to the problems with
temporary cardiac pacing was to ask
anaesthetists to step in to address a
deficiency in general medical training.1 Cen›
tral venous cannulation is an oft performed
and sometimes life saving procedure, and
lack of competence in this technique among
physicians in training suggests that training
needs to be changed.
With recent changes in training in
anaesthetic and intensive care medicine
there is an increasing number of preregistra›
tion training posts in anaesthesia. A growing
number of senior house officer posts in
intensive care medicine is also available to
trainees from all medical backgrounds
where competency based training in a wide
range of procedures, including placement of
central lines, is offered. Failing this almost all
acute hospitals have some form of critical
care unit where trainees and senior physi›
cians are likely to be welcomed in order to
attain and maintain competency in such
procedures. Taking advantage of such
opportunities is surely a better way to
address training issues while encouraging
the development of even closer cooperation
between the two specialties.
Sophie Risebero consultant anaesthetist
Department of Anaesthetics, Worcester Royal
Infirmary, Worcester WR5 1HN
srisebero@hotmail.com
1 Murphy JJ. Problems with temporary cardiac pacing. BMJ
2001;323:527. (9 September.)
Formal training in core procedure is
lacking for specialist registrars in general
internal medicine
Editor—Murphy draws attention to the
deficiencies in the training of general physi›
cians (non›cardiology) in temporary cardiac
pacing.1 The Joint Committee for Higher
Medical Training of the Royal College of
Physicians has stated that training in proce›
dure is mandatory for accreditation in
general (internal) medicine by including it as
one of the “core/essential” procedures of
the curriculum for specialist registrars in this
specialty. In the absence of formal training,
acquisition and maintenance of competence
at temporary cardiac pacing requires oppor›
tunity to perform the procedure. We
therefore used a questionnaire to determine
specialist registrars’ experience in this
technique.
Twenty specialist registrars seeking dual
accreditation in a chosen specialty and gen›
eral internal medicine who participated
regularly in the general medical on call rotas
(18 specialist registrars) or the intensive care
(two) of a 1000 bed teaching hospital
answered a series of questions about their
experience in temporary cardiac pacing.
The number of temporary pacemaker
wire insertions performed by the registrars
varied greatly. Four had inserted between 21
and 50 temporary wires, the chosen
specialty of two of them being intensive care
medicine. Fifteen had inserted fewer than 10
temporary pacing wires (supervised and
unsupervised) during their professional
career, seven had inserted fewer than five,
and one had not inserted any.
Although most of these specialist regis›
trars had some experience of temporary car›
diac pacing, few were currently performing
the procedure often enough to maintain
competence. Only three of the group had
inserted a temporary pacing wire within the
previous 6 months. Seven had performed the
procedure within the previous 12 months, six
between 1 and 2 years previously, and three
more than 2 years previously, with one
specialist registrar not having inserted a tem›
porary wire in the previous 5 years. Ten of the
group thought that they would like to have a
more experienced member of staff to help
them in case of difficulty.
Specialist registrars seeking accredita›
tion in general internal medicine are
currently the most senior doctors in house
to provide temporary cardiac pacing.
Furthermore, they are expected to provide
guidance and training in this procedure to
more junior medical colleagues and subse›
quently assume overall responsibility as
general medical consultants on call. Our
study shows that most specialist registrars do
not perform temporary cardiac pacing often
enough to maintain or even achieve compe›
tence in this procedure. Formal training in
this procedure therefore will be necessary if
it is to remain as a core/essential procedure
required of practitioners of general internal
medicine.
Liam Cormican specialist registrar in respiratory
medicine and general internal medicine
Department of Respiratory Medicine, Thomas Guy
House, Guy’s Hospital, London SE1 9RT
cormitron@yahoo.com
Emma Baker senior lecturer (honorary consultant)
Department of Physiological Medicine, St George’s
Hospital Medical School, London SW17 0RE
1 Murphy JJ. Problems with temporary cardiac pacing. BMJ
2001;323:527. (9 September.)
Novices can reliably and safely perform
temporary pacing from femoral route
Editor—A need for urgent temporary pac›
ing remains in district general hospitals.1
External cardiac pacing is useful but is not
always reliable and can be quite painful.
Transferring patients to a specialist centre
with recurrent syncope or significant hypo›
tension, regardless of the use of isoprena›
line infusions and external pacing is not
acceptable.
What is required is a straightforward and
reliable technique of transvenous temporary
pacing that can be performed by a senior
house officer, specialist registrar, or consult›
ant with no or little recent experience. The
two possibilities are balloon flotation cath›
eters inserted through the subclavian or
jugular vein and semirigid pacing wires
through the femoral vein. Balloon flotation
catheters work well and can be inserted by a
novice with the aid of a simple instruction
diagram, assuming that central access is
achieved.2 Traversing the tricuspid valve can,
however, be difficult in the presence of
severe tricuspid regurgitation.
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The ideal solution for urgent transvenous
temporary pacing by a novice is the femoral
route and a standard wire. The anatomical
landmarks are well defined, and access is reli›
ably achieved. External compression on the
femoral vein allows haemostasis if bleeding
complicates thrombolysis. The temporary
wire readily crosses the tricuspid valve to take
up a stable position, even in the presence of
severe tricuspid reflux. Little manipulation is
required within the heart because the wire
follows a natural curve. This minimises
procedure time and the incidence of ven›
tricular arrhythmias. If there are concerns
regarding incidence of infection the wire can
be renewed with a new wire from the subcla›
vian or jugular as a planned exercise allowing
the possibility for teaching.
We conducted a feasibility study over a
period of eight months to assess the ease with
which senior house officers who had no or
very little pacing experience could undertake
femoral route pacing when instructed by a
specialist registrar in cardiology (group A, 17
patients). A different senior house officer was
invited to perform the procedure each time
after a brief explanation. All achieved access
without complication and a suitable pacing
wire position under the guidance of the
specialist registrar. This group was compared
with the remainder undergoing temporary
pacing, performed by more experienced sen›
ior house officers alone or with supervision
by their non›cardiology consultant (group B,
13 patients). Most in group B used jugular or
subclavian access. Ethics approval was not
sought because the study was a retrospective
comparison of two groups undergoing a
clinically indicated procedure by equally
accepted techniques.
In group A, 1 of the 17 patients (6%)
required repositioning and 10 (59%) were
placed under six minutes compared with 3
(23%) and 6 (46%) of the 13 patients in
group B, respectively. Temporary pacing via
the femoral vein is reliable, safe, and quickly
learnt by novices.
Nigel Clarke cardiology specialist registrar
nigelra.clarke@btinternet.com
Patrick Davey consultant cardiologist
David Sprigings consultant cardiologist
John Birkhead consultant cardiologist
Northampton General Hospital, Northampton
NN1 5BD
1 Murphy JJ. Problems with temporary cardiac pacing. BMJ
2001;323:527. (9 September.)
2 Fergusson JD, Banning AP, Bashir Y Randomised trial of
temporary cardiac pacing with semirigid and balloon›
floatation catheters. Lancet 1997;349:1883.
Mental health services for
children and adolescents
Raised profile of child health services is
welcome
Editor—The announcement of Professor
Aynsley›Green’s appointment as national
director for children’s healthcare services,
follows on the important government
decision to establish a national service
framework for children’s services,
announced last year.1 It is around 18 months
since the BMJ published an article by
Aynsley›Green et al pointing to the neglect
of children at a policy level.2
This neglect applies in a great measure
to the mental health services for children
and adolescents. These services—despite
recent much heralded ringfenced moderni›
sation monies, now discontinued after only
two years—have long waiting lists for
outpatient services and inadequate numbers
of beds for mentally ill young people, who
end up inappropriately on adult wards and
paediatric units.
Child mental health professionals have
been encouraged by the decision of the
Health Secretary, Alan Milburn, to include
child and adolescent mental health services,
along with maternity and social care
services, within the national service frame›
work. These services were excluded from the
recent national service framework for
mental health. Most regard the framework
for children’s services as the proper place to
consider the changes to strategy, workforce,
structures, and resources that are urgently
needed to meet the mental health needs of
the nation’s children. A study conducted by
the Office for National Statistics showed that
10% of children and young people in
England and Wales have an identifiable
mental health disorder. The commonest
conduct disorder, reported by Scott et al to
be amenable to parenting training, costs the
patient, his family, and society dear—in
economic terms, by the age of 28 years,
10.00 times higher than those with no prob›
lems.3 Not all these young people with men›
tal health disorder need or will access
specialist mental health services for children
and adolescents. But the findings underline
the importance of creating health, educa›
tion, and social care services that, together
with the communities in which our families
live, will be appropriately funded to combat
stigma, promote emotional wellbeing, and
address the hitherto unmet mental health
needs of the children.
Caroline Lindsey consultant child and adolescent
psychiatrist
Child and Family Department, Tavistock Clinic,
London NW3 5BA
clindsey@tavi›port.org
1 White C. New child tsar promises shake›up of services.
BMJ 2001;323:302. (11 August.)
2 Aynsley›Green A, Barker M, Burr S, Macfarlane A, Morgan
J, Sibert J, et al. Who is speaking for children and
adolescents and for their health at the policy level? BMJ
2000;321:229›32.
3 Scott S, Spender Q, Doolan M, Jacobs B, Aspland H. Multi›
centre controlled trial of parenting groups for childhood
antisocial behaviour in clinical practice. BMJ 2001;323:
194. (28 July.)
Titles are ridiculous
Editor—Our masters, it seems, have
appointed yet another medical tsar.1 It is odd
that they have yet to appoint a tsarina; even
odder that they have “gone foreign” to find
an unsuitable title. The tsars, after all, were
absolutist Russian rulers whose behaviour,
on occasion, was not what we would expect
in our caring health service. I thought that a
nation so rich in ridiculous titles could have
devised something more appropriate and
British, such as “paediatrician›in›waiting to
the minister’s bedchamber.”
If the men in suits were determined to
add a touch of Eastern exotica to our
governance, they could have turned to their
childhood story books and given us a grand
vizier or two. But once you start delving into
story books, you realise the most appropri›
ate title might be grand panjandrum.
Michael O’Donnell writer and broadcaster
Handon Cottage, Loxhill, Godalming, Surrey
GU8 4BD
michael@odonnell99.freeserve.co.uk
1 White C. New child tsar promises shake›up of services.
BMJ 2001;323:302. (11 August.)
Fabricated or induced illness
in children
Open mind is needed regarding origins
of childhood symptoms and illnesses
Editor—I do not agree with Wilson that
guidance issued by the Department of
Health for consultation is excellent.1 Wilson
admits that the origins of Munchausen syn›
drome by proxy were based in the personal
experience of Roy Meadows.
Is this how paediatric diagnoses are
made, simply on the basis of an individual’s
subjective experience? Especially when such
a “diagnosis” has had such a devastating and
damaging effect on many hundreds of
children and families in the United King›
dom and around the world. Emotional dam›
age is caused to children, their parents, and
siblings from being separated and placed
into state care; or where stigmatised parents,
avoid contact with doctors because they
would be dismissed as child abusers if they
presented their children for medical treat›
ment. Consequently some very ill children
have not received the medical attention they
so desperately needed.
So, Munchausen by proxy is not based
on painstaking research under scientific
conditions? There is no system of verifica›
tion nor validation by an accredited national
medical body? No field testing has been
done over a reasonable period of time? Does
the Royal College of Paediatrics and Child
Health not have a duty and responsibility to
all children and parents to ensure that
paediatric diagnoses are not merely based
on the subjective personal experience of
one paediatrician?.
Wilson also says that a child’s doctor is
not required to clarify whether inappropri›
ate parental care is the result of mental
illness, and yet there are doctors without a
psychiatric qualification who have stated in
evidence to courts in cases of Munchausen
by proxy that the parent has a serious
personality disorder.
The claim by Wilson that rates of
fabricated or induced illness in children are
underestimates is not based in fact. If it were,
then there must be many thousands of
extremely gullible doctors in the United
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Kingdom who can so easily be deceived, and
their ability to diagnose childhood illnesses
is seriously impaired.
I agree with Wilson that we need to have
an open mind regarding the complex
origins of childhood symptoms and ill›
nesses, but unfortunately the Department of
Health’s guidance and Wilson’s letter do not
show such open mindedness.
Charles Pragnell social care management consultant
Social Care Consultants, Redcar and Cleveland
TS10 2JN
1 Wilson R. Fabricated or induced illness in children. BMJ
2001;323;296›7. (11 August.)
Author’s reply
Editor—Pragnell and his work are moti›
vated by his sense of injustice done to some
parents. His remarks have no clear target,
and he seems to wish to support individuals
by claiming that fabricated or induced
illness does not exist. He wishes to protect
parents; I wish to protect children first. He
seems to have a punitive retrospective aim.
Professionals and the Department of
Health, as well as the overwhelming major›
ity of the public, want preventive and
protective action to improve the present
and the future. The Royal College of Paedi›
atrics and Child Health and Department of
Health have used the views of children and
families in drawing up their current
procedures.
I know that Pragnell wants progress too.
Rather than be attracted by the flames of
conflict we should highlight the issues on
which we agree. This may be easier when
the full draft of the royal college’s document
is issued.
Richard Wilson consultant paediatrician
Kingston NHS Trust, Kingston KT2 7AZ
Endometriosis
Emphasis on medical treatment is
misleading
Editor—In his review on endometriosis,
Prentice sets out management strategies for
treating painful symptoms resulting from
endometriosis.1 He concludes that the first
line treatment should be medical and that
surgery should be reserved for cases in which
medical treatment has failed or for patients
with severe disease. We believe that the
emphasis on medical treatment and the
assertion that controversy exists over the pre›
cise role of surgery are misleading and may
be responsible for physicians mismanaging
their patients.
The evidence from randomised control›
led trials for the medical and surgical
management of endometriosis has recently
been reviewed.2 A critical summary of the
medical management has shown that there
is little difference in effectiveness of various
medical treatments, which only last while
patients remain on treatment. The review
also showed that surgical management is
effective in the treatment of both painful
symptoms and subfertility. Furthermore,
there is a wealth of grade II and III evidence
in the literature which supports laparo›
scopic surgery as the primary treatment
modality for all stages of endometriosis.3
We believe that in the United Kingdom
endometriosis is misdiagnosed in many
patients who are having a laparoscopy, and
many are not treated adequately because of
the emphasis on medical management
strategies.3 This almost certainly reflects the
fact that only a few surgeons in the United
Kingdom have the advanced endoscopy
skills required to diagnose and then treat
the disease laparoscopically. This is in
marked contrast to the situation in the rest
of Europe and North America, where surgi›
cal techniques using minimal access were
first developed.
We recommend that medical treatments
be used by primary care doctors for the short
to medium term to control painful symp›
toms, before referral to hospital for surgery or
while the patient is on the waiting list for sur›
gery. Patients should be referred to units
where laparoscopic diagnosis and surgery
can be carried out during the same operation.
Conservative, excisional, or ablative endo›
scopic surgery and not medical treatment
should be the first line management of
patients with endometriosis. This applies to
women with any stage of the disease, but par›
ticularly those with endometriotic cysts, or
infiltrating rectovaginal disease.4 5
Kevin D Jones clinical fellow in gynaecological
endoscopic surgery
Christopher Sutton consultant gynaecologist
Royal Surrey County Hospital, Guildford GU2 5XX
1 Prentice A. Endometriosis. Regular review. BMJ 2001;323:
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321›32.
3 Garry R. Endometriosis: an invasive disease. Gynaecol
Endoscopy 2001;10:79›83.
4 Jones KD, Sutton CJG. Laparoscopic management of
ovarian endometriomas: a critical review of current
practice. Curr Opin Obstet Gynaecol 2000;12:309›17.
5 Jones KD, Sutton CJG. Arcus taurinus: the mother and
father of all LUNAs. Gynaecol Endoscopy 2001;10:83›91.
Clinicians and patients should be aware
of association between endometriosis and
malignancies
Editor—Prentice’s review highlights the
difficulties encountered in clinical practice
in relation to endometriosis.1 Clinicians
should use abdominal or transvaginal ultra›
sound imaging of the pelvis when women
present with pelvic pain, dysmenorrhoea, or
dyspareunia to ascertain whether the
ovaries are normal or contain endometri›
otic cysts. The presence of these cysts may
indicate more widespread disease in the
pelvis. This is important for women about
to undergo major gynaecological surgery as
unexpected extensive and severe endome›
triosis may lead to more surgery than had
been discussed preoperatively or consented
to by the patient. This has medicolegal
implications.
Another issue is that of the association
between endometriosis and ovarian cancer.
So far this has not been a subject that is
discussed in full with patients. But a study of
1000 cases of endometriosis reported that, in
8.8% of cases, malignancy and endometriosis
were both present in the same organ, but not
necessarily microscopically contiguous, and
higher if the lesions were located in different
organs.2 Malignancies were also more com›
monly found in ovaries that contained
endometriosis. Clear cell and endometroid
carcinomas were the malignancies most com›
monly seen in endometriotic ovaries, and
there was clear association between these his›
tological types and endometriosis. Clinicians
and patients must be made aware of this
association, especially when surgery is con›
templated in comparatively young women.
Nazar N Amso senior lecturer and honorary
consultant obstetrics and gynaecology
University Hospital of Wales, Cardiff, CF14 4XN
amsonn@cf.ac.uk
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Media could be used to better
effect than inducing fear
Editor—Lightfoot et al discussed responses
to bioterrorist threats.1 One of the aspects
that I found most interesting about the
recent anthrax releases in the United States
is the apparently disproportionate fear that
they have produced among the population,
fuelled, I think, by the media coverage they
have been given.
According to a report published by the
US Centers for Disease Control and
Prevention on 25 September 2001, in 1999,
28 874 people died of firearms injuries,
19 102 of drug related causes, and 19 171
of alcohol related causes. Neither the statis›
tics on drugs deaths nor those on alcohol
related deaths include accidents, homicides,
or other causes indirectly related to their
use. Given that the media are able to wield
such massive influence, perhaps in the
hoped for “new world order” they can do so
in more useful ways.
Tim Kerruish consultant, emergency medicine
Emergency Department, Dunedin Hospital,
201 Great King Street, Private Bag 1921, Dunedin,
New Zealand
kerruish@voyager.co.nz
1 Lightfoot N, Wale M, Spencer R, Nicoll A. Appropriate
responses to bioterrorist threats. BMJ 2001;323:877›8.
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